Global Drug Delivery Devices Market Expected to Grow to $100.1 Billion in 2026 at a CAGR of 4.5%
July 22, 2022 06:28 ET
|
Research and Markets
Dublin, July 22, 2022 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Devices Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global drug delivery devices market...
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
June 23, 2022 07:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational
June 17, 2022 12:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Global Drug Delivery Partnering Deals Terms and Agreements 2015-2022: Access to Over 1,500 Deal Records of Actual Deals by Company A-Z, Stage of Development, Deal Type, Therapy Focus, and Technology
June 13, 2022 04:13 ET
|
Research and Markets
Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Drug Delivery...
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
June 02, 2022 14:40 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders
May 24, 2022 06:45 ET
|
Cingulate Inc.
Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily CTx-2103 is the Third Candidate Using...
Cingulate to Present at H.C. Wainwright Global Investment Conference
May 18, 2022 17:20 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update
May 12, 2022 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Global Pharmaceutical Drug Delivery Markets Analysis & Forecasts, 2014-2021 & 2022-2032
April 19, 2022 05:33 ET
|
Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Drug Delivery Market 2022-2032" report has been added to ResearchAndMarkets.com's offering. This recent market study on the...
Geocann and Averix Bio form a strategic partnership to supply the global marketplace with pharmaceutical API phytocannabinoid ingredients formulated with a clinically proven drug delivery system technology
April 13, 2022 09:04 ET
|
Geocann
FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Geocann is proud to announce a strategic partnership with Averix Bio that will bring U.S.-produced API phytocannabinoid ingredients and...